Physiological Sciences Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, United States of America.
PLoS One. 2012;7(12):e51363. doi: 10.1371/journal.pone.0051363. Epub 2012 Dec 7.
Treatment of head and neck cancer with radiation often results in damage to surrounding normal tissues such as salivary glands. Permanent loss of function in the salivary glands often leads patients to discontinue treatment due to incapacitating side effects. It has previously been shown that IGF-1 suppresses radiation-induced apoptosis and enhances G2/M arrest leading to preservation of salivary gland function. In an effort to recapitulate the effects of IGF-1, as well as increase the likelihood of translating these findings to the clinic, the small molecule therapeutic Roscovitine, is being tested. Roscovitine is a cyclin-dependent kinase inhibitor that acts to transiently inhibit cell cycle progression and allow for DNA repair in damaged tissues.
METHODOLOGY/PRINCIPAL FINDINGS: Treatment with Roscovitine prior to irradiation induced a significant increase in the percentage of cells in the G(2)/M phase, as demonstrated by flow cytometry. In contrast, mice treated with radiation exhibit no differences in the percentage of cells in G(2)/M when compared to unirradiated controls. Similar to previous studies utilizing IGF-1, pretreatment with Roscovitine leads to a significant up-regulation of p21 expression and a significant decrease in the number of PCNA positive cells. Radiation treatment leads to a significant increase in activated caspase-3 positive salivary acinar cells, which is suppressed by pretreatment with Roscovitine. Administration of Roscovitine prior to targeted head and neck irradiation preserves normal tissue function in mouse parotid salivary glands, both acutely and chronically, as measured by salivary output.
CONCLUSIONS/SIGNIFICANCE: These studies suggest that induction of transient G(2)/M cell cycle arrest by Roscovitine allows for suppression of apoptosis, thus preserving normal salivary function following targeted head and neck irradiation. This could have an important clinical impact by preventing the negative side effects of radiation therapy in surrounding normal tissues.
头颈部癌症的放射治疗常导致周围正常组织如唾液腺的损伤。唾液腺功能的永久丧失常常导致患者因无法忍受的副作用而停止治疗。先前的研究表明,IGF-1 抑制辐射诱导的细胞凋亡,增强 G2/M 期阻滞,从而维持唾液腺功能。为了重现 IGF-1 的作用,并增加将这些发现转化为临床应用的可能性,正在测试小分子治疗药物 Roscovitine。Roscovitine 是一种细胞周期蛋白依赖性激酶抑制剂,可暂时抑制细胞周期进程,允许受损组织进行 DNA 修复。
方法/主要发现:在照射前用 Roscovitine 治疗可显著增加细胞在 G2/M 期的比例,如流式细胞术所示。相比之下,与未照射的对照组相比,用辐射处理的小鼠在 G2/M 期的细胞比例没有差异。与先前利用 IGF-1 的研究相似,Roscovitine 的预处理导致 p21 表达的显著上调和 PCNA 阳性细胞数量的显著减少。辐射处理导致激活的 caspase-3 阳性唾液腺泡细胞显著增加,而 Roscovitine 的预处理抑制了这一增加。在靶向头颈部照射前给予 Roscovitine 可在急性和慢性时保持小鼠腮腺唾液腺的正常组织功能,这可通过唾液分泌量来衡量。
结论/意义:这些研究表明,Roscovitine 诱导的短暂 G2/M 期细胞周期阻滞允许抑制细胞凋亡,从而在靶向头颈部照射后保留正常的唾液腺功能。这可能具有重要的临床意义,因为它可以防止放射治疗对周围正常组织的负面副作用。